Recombinant mutant human tumor necrosis factor(Taihe Biology)

重组改构人肿瘤坏死因子（泰禾生物）

Report date: 2025/03/11 17:01:50

Base Information

Drug NameRecombinant mutant human tumor necrosis factor(Taihe Biology)
Drug Alias Name注射用重组改构人肿瘤坏死因子
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionTumor necrosis factor receptor agonists
TargetsTumor necrosis factor receptor
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesGuangdong Taihe Biology Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesGuangdong Taihe Biology Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A